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Abstract
Persistent infection with hepatitis C virus (HCV) is associated with an increased risk of 
hepatocellular carcinoma (HCC). Cancer typically develops in a setting of chronic hepatic 
inflammation and advanced fibrosis or cirrhosis, and such tissue represents a pre-neoplastic 
“cancer field”. However, not all persistent infections progress to HCC and a combination of viral 
and host immune factors likely to contribute to carcinogenesis. HCV may disrupt cellular 
pathways involved in detecting and responding to DNA damage, potentially adding to the risk of 
cancer. Efforts to unravel how HCV promotes HCC are hindered by lack of a robust small animal 
model, but a better understanding of molecular mechanisms could identify novel biomarkers for 
early detection and allow for development of improved therapies.
INTRODUCTION
Approximately 3.5 million persons in the USA are persistently infected with hepatitis C 
virus (HCV) [1]. Chronic hepatitis C is a slowly progressing disease and many infected 
persons remain asymptomatic for decades after initial infection. However, the long-term 
complications of infection are substantial, and include hepatic fibrosis, cirrhosis, and 
hepatocellular carcinoma (HCC). Many currently asymptomatic individuals acquired 
infection prior to the identification of HCV as the etiologic agent of chronic ‘non-A non-B’ 
hepatitis in 1989 [2]. Because the likelihood of disease increases with the length of 
infection, the incidence of HCV-associated cirrhosis and HCC has been increasing as this 
cohort ages and is predicted to reach a peak within the next decade [3]. In addition, a recent 
surge in injection drug use among young, largely white, non-urban Americans is leading to 
worrisome increases in the incidence of new HCV infections, and is likely predictive of 
future increases in liver cancer. Compounding the impact of such increases in HCC 
incidence, the five-year survival rate of patients with liver cancer has remained low (~15%) 
within the U.S.
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As a single-stranded, positive-sense RNA virus (Figure 1), replicating primarily if not 
exclusively within hepatocytes, HCV is unique among cancer-causing viruses. Its 
intracellular replication cycle is entirely cytoplasmic and without potential for integration of 
viral genome into host chromosomal DNA. Similar to infection with other oncogenic 
viruses, only a minority of chronically infected persons develop cancer, suggesting that viral 
elements co-operate with host and environmental factors to promote tumorigenesis. 
Transgenic mice with liver-specific expression of HCV proteins are at increased risk for 
hepatocellular carcinoma [4,5]. However, the absence of a tractable small animal model of 
HCV infection and hepatocellular carcinogenesis has slowed progress in this field, such that 
many questions concerning how HCV causes liver cancer remain unresolved.
Indirect effects of chronic inflammation: a pro-carcinogenic environment
Within the infected liver, double-stranded viral RNA replication intermediates are sensed by 
host pathogen-associated molecular pattern (PAMP) receptors resulting in the activation of 
the transcription factors IRF3/7 and NF-κB, and the induction of interferons and related 
interferon-stimulated genes (ISGs). HCV has evolved several mechanisms that antagonize 
these responses (reviewed in [6]), and these may contribute to viral persistence by 
attenuating cell-intrinsic innate immune responses. Despite this virus antagonism, antiviral 
signaling pathways are activated during persistent HCV infection resulting in increased 
intrahepatic ISG transcription [7]. Subsequent adaptive immune responses, in particular 
virus-specific CD8+ cytotoxic T lymphocytes [8,9], while critical for resolving the infection, 
succeed in clearing the virus only in a minority (~30-40%) of cases [10]. Thus, most 
infected persons develop lifelong, persistent infection. Such individuals are at risk for 
protracted but ultimately ineffective immune responses leading to chronic immune-mediated 
inflammation with repeated cycles of hepatocyte destruction and regeneration.
What are the effects of chronic inflammation?—Persistent immune-mediated 
hepatic inflammation and associated fibrogenic wound-healing responses are likely to be 
important drivers of liver cancer in chronic hepatitis C (Figure 2). Activated inflammatory 
cells promote a pro-carcinogenic microenvironment by releasing reactive oxygen (ROS) and 
nitrogen (RNS) species and induce lipid peroxidation [11]. The expression of some HCV 
proteins, in particular core and NS5A, may also add directly to the induction of oxidative 
stress (see below). The HCV RNA replicase complex possesses a unique ‘sensor’ that 
responds to lipid peroxidation by down-regulating viral RNA synthesis, thereby maintaining 
replication at low levels and minimizing oxidative damage [12]. While this may facilitate 
HCV persistence, hepatic oxidative DNA damage is nonetheless common in chronic 
hepatitis C [13-15]. Such DNA damage is likely not heritable in terminally differentiated 
cells. However, in the context of inflammatory liver disease and hepatocellular necrosis 
associated with chronic hepatitis C, regenerative pathways may be activated allowing 
dedifferentiation and proliferation to replace damaged tissue.
Without treatment, approximately 20% of persons with chronic hepatitis C develop severe 
scarring of the liver, or cirrhosis. Most (perhaps 90%) HCV-associated cancers arise in a 
background of advanced fibrosis or cirrhosis. A progression of lesions (large regenerative 
nodules, low-grade and high-grade dysplastic nodules) have been identified in the cirrhotic 
Mitchell et al. Page 2













liver that likely represent HCC precursors [16]. Thus, during the development of 
hepatocellular cancer, the cirrhotic liver may be considered a pre-neoplastic “cancer field” 
comprised of genetically abnormal but non-neoplastic tissue that is at high risk for malignant 
transformation (Figure 2) [17]. Accordingly, HCC is often multifocal in origin in chronic 
hepatitis C [18]. Cells within this precancerous field already contain mutations that 
predispose to the cancerous phenotype (discussed below).
What is the impact of chronic hepatocyte turnover?—Over decades of chronic 
HCV infection, apoptosis of infected hepatocytes (either immune- or virus-mediated) with 
compensatory hepatocellular proliferation may be strongly pro-carcinogenic. Tumor-
promoting effects of apoptosis have been demonstrated in transgenic mouse models where 
liver-specific knockout of anti-apoptotic proteins such as Mcl-1 promote cancer [19]. 
Conversely, knockout of the proapoptotic p53 up-regulated modulator of apoptosis (PUMA, 
or Bbc3) inhibits tumor development following exposure to the chemical carcinogen, 
diethylnitrosamine [20].
HCV-associated HCC may be considered, like other cancers, a disease of somatic evolution 
where individual cells are the unit of reproduction [21]. In chronic hepatitis C, the 
generation of ROS by either viral or immune-mediated mechanisms could create a pro-
mutagenic environment, while chronic hepatocellular turnover could select for cells with 
genetic or epigenetic changes that confer growth advantages allowing clonal expansion 
(Figure 2).
Direct effects of HCV on the infected hepatocyte
Surprisingly, only a minority of hepatocytes contain detectable viral RNA or proteins within 
the HCV-infected liver [22,23], suggesting that most cells remain uninfected. The factors 
restricting replication are not well understood, and whether cancer arises from an infected 
hepatocyte or an uninfected bystander cell remains an open question.
Does HCV infection render a cell prone to accumulate genetic alterations?—
HCCs exhibit a high degree of genetic heterogeneity indicative of a fundamental loss of 
genomic stability during hepatocellular carcinogenesis [24]. HCV infection is likely to 
contribute to this genetic instability directly by inducing the generation of reactive oxygen 
species (ROS) with consequent DNA damage (Figure 2). Although immune-mediated 
inflammation is at least partly responsible, as discussed above, expression of either the HCV 
core protein or NS5A, a component of the viral replicase, increases ROS levels and 
promotes oxidative stress in transgenic mice as well as cultured cells [25-29]. These effects 
have been attributed to mitochondrial and ER stress initiated by core and NS5A, 
respectively [25,27,28], although it is uncertain whether these proteins are expressed in 
sufficient abundance for such direct effects to occur within the infected liver.
In addition to promoting DNA damage, some evidence suggests HCV infection 
compromises the ability of host cells to detect and repair damaged DNA. The ataxia 
telangiectasia mutated (ATM) kinase plays a central role in initiating cellular responses to 
double-strand DNA breaks [30]. Overexpression studies suggest that core, NS3/4A (the 
major viral protease), and NS5B (RNA-dependent RNA polymerase) are capable of 
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interacting with components of the ATM-driven response, thereby interfering with host 
DNA repair [31-33]. Although these interactions await confirmation in the context of viral 
replication, HCV infection impairs phosphorylation of an ATM substrate, histone 2A.X 
(H2AX), in Huh-7.5 cells [34]. Phosphorylated H2AX (γ-H2AX) normally acts as a 
platform for the recruitment of DNA repair factors to the sites of DNA damage [35]. As 
such, inhibition of γ-H2AX might disrupt DNA repair and contribute to genomic instability 
during HCV infection. Unfortunately, the small proportion of hepatocytes infected with 
HCV in vivo coupled with low-level expression of viral proteins makes it extraordinarily 
difficult to confirm or refute such effects in primary human tissues.
The p53 protein is a critical tumor suppressor that coordinates cell-cycle arrest, senescence, 
and apoptosis in response to DNA damage and other stresses [36]. Mutations that disrupt 
p53 function are associated with the vast majority of human cancers, including HCC 
[37,38]. Numerous studies have indicated that HCV proteins, including core, NS3, and 
NS5A, can interact with p53 when overexpressed in cell culture (for an extensive review see 
[39]). However, these studies have yielded often-conflicting results as to the impact of HCV 
proteins on p53 activity, and interactions between HCV proteins and p53 have yet to be 
reported in the context of infection. The overall impact of HCV infection on p53 function 
remains undefined, largely because the cell-lines that are most permissive for HCV (Huh-7 
hepatoma cells and their derivatives) express a mutated, inactive form of p53 [40,41].
Does HCV infection promote hepatocellular proliferation?—A common feature of 
oncogenic viruses is their ability to increase cell proliferation, particularly through the 
inactivation of host tumor suppressors [42]. The retinoblastoma (Rb) protein restricts cell 
proliferation by repressing the activation of E2F transcription factors necessary for S-phase 
entry in the cell cycle [43]. HCV infection negatively regulates Rb abundance in cell culture 
[44-46]. This effect is mediated by the NS5B polymerase, which binds Rb via an LxCxE 
motif bearing sequence homology to the Rb-binding motifs of DNA virus oncoproteins [46]. 
NS5B mediates Rb relocalization, promotes proteasomal degradation of Rb in association 
with the host ubiquitin ligase E6AP, and activates E2F-responsive promoters [45,46]. Rb is 
essential for optimal innate immune responses in hepatocytes [47], explaining why an RNA 
virus such as HCV (that does not depend upon DNA synthesis for replication) would have 
evolved such a mechanism.
Despite E2F activation, however, HCV infection reduces cell proliferation and triggers cell-
cycle arrest in cultured cells [48,49]. These findings point towards opposing pro- and anti-
proliferative effects during HCV infection. Consistent with this hypothesis, normally 
quiescent hepatocytes show increased entry into the cell cycle within HCV-infected livers, 
but markers of G1 arrest are also elevated [50]. However, it is unclear to what extent cell-
cycle perturbations observed within the liver represent direct effects of HCV infection since 
only a minority of hepatocytes are typically infected in vivo [7,22]. It is possible that G1 
arrest may be triggered by endogenous or therapeutically administered interferon [51].
HCV may also deregulate the Wnt/β-catenin signaling pathway. This pathway is normally 
activated upon binding of Wnt ligands to the Frizzled receptor and ultimately triggers 
activation of the transcription factor β-catenin and consequent upregulation of cellular pro-
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survival genes. Mutations within this pathway, including activating mutations within β-
catenin, occur frequently in HCC, indicating an important role for this pathway in 
hepatocellular carcinogenesis [37]. Both core and NS5A are capable of activating β-catenin 
when overexpressed in cell culture [52-55]. Likewise, β-catenin is activated in HCV 
transgenic mice, wherein it drives overexpression of the oncogene c-myc and thereby 
contributes to oxidative DNA damage and impaired cell-cycle arrest [26].
Do HCV-infected cells evade apoptosis?—The role of apoptosis in HCV-related 
HCC is likely complex. On one hand, apoptosis is expected to exert tumor suppressive 
effects through the removal of aberrant and infected cells. On the other hand, successive 
rounds of apoptotic cell death with subsequent regenerative proliferation could also 
contribute to carcinogenesis as discussed above, particularly in an environment of oxidative 
stress and genomic instability.
Apoptosis can function as a potent antiviral defense, and many viruses thus suppress this 
host response [56,57]. Whether HCV similarly restricts apoptosis remains unclear. 
Individual HCV proteins, including core, E2, NS2, NS3, and NS5A, inhibit apoptosis when 
overexpressed (reviewed in [39]), whereas HCV infection can induce apoptosis in Huh-7 
cells and further sensitize them to death receptor-mediated apoptosis [48,49,58-60]. 
However, most studies of HCV-induced apoptosis have utilized an atypical, robustly 
replicating, infectious molecular clone of HCV, JFH1 or its derivatives. JFH1 replication is 
not suppressed by lipid peroxidation [12], and it may trigger apoptosis through artificially 
high-levels of replication and viral protein expression that do not reflect HCV infections in 
vivo [7,22]. An alternate molecular clone, H77S.3, replicates at lower levels in cell culture 
and elicits little apoptosis [48]. Virus produced in cell culture from a closely related clone, 
H77S.2, established persistent infection in a chimpanzee, whereas cell culture-derived JFH1 
virus infects chimpanzees but does not establish persistence [61]. Moreover, passage of 
JFH1 in chimpanzees resulted in adaptive mutations that rendered it less pro-apoptotic than 
wild-type JFH1 [62]. Although only a small number of chimpanzees were involved in these 
studies, they suggest evasion of apoptosis may be important for establishing persistent 
infection.
What genetic changes contribute to the “cancer field”?
What can we learn from studying the genetics of HCC?—Although it is possible to 
identify driver genes in HCC by whole exome sequencing [37,63,64], no unique driver 
genes have yet been linked specifically to HCV infection [64]. A better understanding of 
genetic and epigenetic changes that drive HCC progression may ultimately allow for 
improved, personalized therapies, but the genetic diversity of HCC makes such studies very 
challenging [24].
What are the earliest genetic changes in HCC?—The stepwise accumulation of 
mutations in HCC is poorly understood. Nonetheless, mutations identified in abnormal, pre-
neoplastic tissue may be predictive of progression to HCC. Mutations in the telomerase 
reverse transcriptase (TERT) promoter are frequently present in high-grade dysplastic 
nodules (19%) and early HCC (61%) in cirrhosis of several different etiologies, including 
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HCV infection [65,66]. Thus TERT promoter mutations represent one of the earliest 
recognized genetic changes in hepatocellular carcinogenesis, and could contribute to the 
cancer field effect in cirrhosis.
What is the cellular origin of HCV-associated HCC?—The precise nature of the 
founder cell in HCC is also poorly understood. Proliferation is essential for a mutation 
arising in a pre-neoplastic cell to spread within a population of such cells. Both mature 
hepatocytes and hepatic progenitor cells are long-lived cells that are capable of repopulation 
following liver injury, and either could be the source of HCC founder cells in chronic HCV 
infection [67]. As discussed above, it is not clear whether HCV-associated HCC arises from 
infected or uninfected cells [68].
An interesting but unanswered question is whether HCV is able to replicate within abnormal 
hepatocytes in dysplastic nodules, and thus might act co-operatively with mutations that 
arise early in the progression to cancer. Expression of the liver-specific micro-RNA, 
miR-122, is often lost during progression to HCC, but is relatively conserved in HCV-
associated versus hepatitis B virus (HBV)-associated cancer [69]. Since miR-122 is a critical 
pro-viral host factor for HCV, this suggests that HCV infection of founder cells may be 
important at some stage of this process.
What factors enhance the risk of HCC development in chronic hepatitis C?
Host and environmental factors—While the progression of liver disease is highly 
variable amongst chronically-infected persons, 15-25% progress to cirrhosis by 25-30 years 
[70]. HCC occurs primarily in persons with cirrhosis, and approximately 20% of cirrhotic 
individuals ultimately progress to cancer [71]. Such progression is exacerbated by a number 
of risk factors, including alcohol consumption, older age, male gender, obesity, diabetes, and 
co-infection with human immunodeficiency virus (HIV) or HBV [72].
Genetic risk factors for HCC development are less well defined. However, genome-wide 
association studies (GWAS) have revealed several single nucleotide polymorphisms (SNPs) 
associated with HCC development in HCV-infected persons [73,74]. A SNP located 
upstream of the MHC class I polypeptide-related sequence A (MICA) gene was associated 
with a slightly elevated risk for HCC [73]. This SNP appears to influence MICA expression 
levels, but it is not clear whether it increases the risk of cancer per se, or acts indirectly by 
influencing progression to cirrhosis. A second GWAS identified an intronic SNP within the 
DEP domain containing 5 (DEPDC5) locus that nearly doubled the risk of HCC [74]. Both 
GWAS studies were conducted within Japanese populations, raising the question of whether 
genetic determinants of HCC vary between ethnic groups. Indeed, an independent study of a 
Caucasian cohort revealed a reverse correlation between the MICA SNP and HCC risk, and 
also identified a SNP within the HLA complex P5 (HCP5) locus upstream of MICA 
associated with an increased risk of HCC in both Caucasian and Japanese populations [75]. 
The DEPDC5 SNP was not associated with cancer in the Caucasian cohort, further 
highlighting differences in genetic determinants of HCC across ethnicities.
Viral factors—There are seven different genotypes of HCV that vary by over 30% at the 
nucleotide level. Epidemiological studies suggest that HCC risk may differ amongst these 
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genotypes, as genotypes 1b and 3 are associated more commonly with HCC than other 
genotypes [76,77]. In contrast, genotype 2 may be associated with a lower risk of HCC [77]. 
The mechanisms underlying these potential genotype-specific differences in HCC risk are 
not clear, nor is it proven that such differences do not arise from genetic or other differences 
in the infected host populations.
How will new HCV antivirals impact the incidence of HCC?
Over the last few years, the introduction of potent direct-acting antiviral (DAA) drugs 
targeting the NS3/4A protease, NS5A, or the NS5B polymerase has revolutionized the 
treatment of chronic hepatitis C. All oral combinations of these DAAs are well tolerated, 
and typically achieve a sustained virologic response (“SVR”) in 90-95% of patients with 
genotype 1 infections after only 12 weeks of therapy [78]. Patients with SVR are truly cured 
of the infection, as HCV does not archive its genome like HIV or HBV. These new drugs 
thus have the potential to substantially reduce HCC incidence over the coming decades. 
Several cohort studies demonstrate that SVR achieved with older interferon-based regimens 
reduces, but does not completely eliminate the risk of HCC in cirrhotic patients (reviewed in 
[79]). It is likely, but not yet proven, that successful DAA therapy will match these results. 
Nonetheless, HCC typically grows slowly and may not become clinically evident for many 
months [80]. Studies are needed to determine how long and to what extent the risk of HCC 
will persist in successfully treated patients. Until these questions are answered, screening for 
HCC will remain important for those patients achieving SVR.
What does the future hold?
A better understanding of the molecular drivers of HCV-associated HCC is likely to result in 
improved and increasingly personalized therapies for this cancer with attendant increases in 
five-year survival rates. Improved screening and early diagnostic modalities are also likely, 
along with reductions in the numbers of individuals reaching advanced stages of HCV-
related liver disease due to continued improvements in antiviral therapy. Despite this, 
however, HCV-associated liver cancer will remain an important public health problem for 
the foreseeable future. There are several reasons for this. First, many infected persons with 
chronic hepatitis C have no access to new DAAs, either because of their high cost or lack of 
medical insurance. Second, because of coexisting conditions, the potential for drug-drug 
interactions, and/or HCV genotype-specific differences in antiviral response, a substantial 
proportion of patients remain difficult to treat with DAAs. Additionally, a large fraction of 
individuals are simply unaware of their infection until they develop symptoms of advanced 
liver disease [1]. And, not to be overlooked, persons fortunate enough to achieve SVR lack 
protective immunity and are at risk for re-infection. Thus, the elimination of HCV-
associated liver cancer seems a far-off and potentially elusive goal, and one that is unlikely 
to be achieved without development of an effective HCV vaccine.
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• The incidence of HCV-associated liver cancer will rise over the next decade.
• Chronic inflammation and hepatic fibrosis are important drivers of liver cancer.
• HCV-infected cirrhotic liver represents a “field of cancerization”.
• Genetic studies highlight a role for host genome instability in carcinogenesis.
• Virus disruption of host responses to DNA damage may contribute to HCC.
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Figure 1. Organization of the 9.7 kb positive-sense HCV RNA genome
5’ and 3’ untranslated regions (UTRs) contain cis-acting elements essential for virus 
replication, including a 5’ internal ribosome entry site (IRES) that drives cap-independent 
expression of a polyprotein (box) that is processed into 10 mature viral proteins by a 
combination of host and viral proteases. Their functions are highlighted above the genome. 
The core (C) protein and envelope glycoproteins E1 and E2 are structural components of the 
virion. Nonstructural (NS) proteins possess functions necessary for replication, including 
helicase (NS3), protease (NS2 and NS3/4A), and RNA-dependent RNA polymerase (NS5B) 
activities. NS4B and NS5A drive formation of the ‘membranous web’, a cytoplasmic 
structure where these proteins accumulate to direct viral RNA synthesis. NS2 and NS5A 
also function in virion assembly, whereas p7 is essential for egress. Virus-host interactions 
that may contribute to HCC development are highlighted below the genome. Core and 
NS5A expression have been linked to the generation of ROS that may contribute to host 
DNA damage. Multiple HCV proteins interact with and modulate host pathways to facilitate 
virus replication and may in theory promote carcinogenesis.
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Figure 2. Model for HCV-associated carcinogenesis
Hepatocellular carcinoma (HCC) likely results from a combination of indirect host- and 
direct HCV-mediated mechanisms. Persistent immune-mediated inflammation, coupled with 
expression of core and NS5A, generates ROS that trigger oxidative DNA damage. HCV 
infection further compromises host genome stability by impairing DNA repair pathways. 
Repeated cycles of hepatocellular destruction with regenerative proliferation and progressive 
fibrosis within this pro-mutagenic environment result in a “cancer field” comprised of pre-
neoplastic but genetically-altered hepatocytes. Continued hepatocellular turnover may, in 
turn, select for aberrant hepatocytes with growth advantages. Whether HCC arises directly 
from HCV-infected hepatocytes remains unclear, although HCV infection may enhance 
survival of abnormal hepatocytes by promoting cell proliferation and inhibiting apoptosis. 
Ultimately, these combined mechanisms may select for transformed cells, culminating in 
development of HCC over 2-3 decades of persistent HCV infection.
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